Cardiol Therapeutics - Class A opened at $1.01, in line with its previous close of $1.01. In the last trading session, the stock traded between $0.97 and $1.07. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cardiol Therapeutics - Class A is now worth
$ 42.06
Resulting in a loss of
$ 57.94 (57.94%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.03 (+3.27%)
Day High
$1.07
Day Low
$0.97
Day Open
$1.01
Prev Close
$1.01
Volume
4,11,914
1W Return
2.56%
1M Return
-12.72%
3M Return
-30.70%
6M Return
-21.87%
1Y Return
0.29%
Fundamentals
Market Cap ($ Mn)
122
PE Ratio
-
PB Ratio
14.99
PEG Ratio
-
ROE
-207.32%
ROCE
-210.40%
EPS (TTM)
$-0.05
Investment Returns
1 Week
2.56%
1 Month
-12.72%
3 Months
-30.70%
6 Months
-21.87%
9 Months
-1.60%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
23Sep
Cardiol expands MAVERIC trial to 150 patients, shifts topline to mid-2027
Expanded Phase III MAVERIC trial enrollment to up to 150 patients. Original 110-patient target reached ahead of September 2026 guidance. Topline results shifted to mid-2027 from previous Q1 2027 estimate. Cash runway extends into Q1 2028 to fund expanded study completion.
1mo ago
11Sep
Cardiol Therapeutics files $150M shelf prospectus for future offerings
Cardiol Therapeutics files base shelf prospectus for up to $150 million in securities. Filing covers Class A common shares, debt, warrants, and subscription receipts. Registration submitted to Canadian regulators and US SEC under Multijurisdictional Disclosure System. No immediate offering; filings valid for 25 months once effective.
2mo ago
15Jul
HC Wainwright reiterates Buy on Cardiol Therapeutics
HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Cardiol Therapeutics, maintaining a price target of $9. The endorsement underscores the analyst's confidence in the company's current valuation and future performance prospects.
4mo ago
9Jul
Cardiol Therapeutics to join B. Riley Summit fireside chat
Cardiol Therapeutics Inc. will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16, 2026. The company is advancing therapies for heart disease, including CardiolRx™ for pericarditis and myocarditis, and CRD-38 for heart failure.
Cardiol Therapeutics Inc. held its Annual General Meeting of Shareholders on June 24, 2026, where shareholders approved all management resolutions. The election of eight directors, including Dr. Guillermo Torre-Amione and David Elsley, was confirmed with vote counts ranging from 96.24% to 99.19%. BDO Canada LLP was appointed as the auditor for the upcoming fiscal year.
